neovascular age-related macular degeneration
Study: Third of nAMD patients safely stopped eye injections
A new study has shown up to a third of neovascular age-related macular degeneration (nAMD) patients may safely be ...
Artificial intelligence: eyecare’s friend of foe?
Eyetelligence is a new Australian-developed AI system helping clinicians screen for three types of eye disease. PROFESSOR MING HE – ...
Annual out-of-pocket eye injection costs to double to $3,900 under rebate cut – modelling
Prominent Australian Ms Ita Buttrose has used a National Press Club address to reveal alarming new data showing that 47,000 ...
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related ...
Australia trial commences for ‘game-changer’ retinal disease eye drop
A clinical trial is under way in Australia for a novel eye drop treatment for retinal vascular diseases that could ...
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to ...
Opthea meets US and European regulators over Phase 3 trial
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel ...
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met ...
Telehealth to continue gathering pace post-pandemic
Rapid uptake of telehealth services amid the COVID-19 pandemic is energising research focused on new ways to remotely diagnose and ...